Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Technology Sector · Fidelity

Fidelity Advisor Biotechnology Fund Class C (FBTCX)

Ticker FBTCX · · Holdings as of Jul 31, 2026

Expense ratio
1.69%$169/yr per $10k
5-yr return
+6.8%annualized
1-yr return
+37.5%as of Sep 2026
Net assets
$2.2Ball share classes
Holdings
129

Bottom line

Is FBTCX a good fund? The bottom line

FBTCX is the Class C share class of Fidelity Advisor Biotechnology Fund, a managed technology sector mutual fund from Fidelity.

Annual fees run 1.69% — about $169 a year on every $10,000 invested, more expensive than 90% of technology sector funds we track.

It returned +37.5% over one year, +6.8% a year over five years, +7.7% a year over ten (as of Sep 30, 2026, per its prospectus).

With $2.2 billion in net assets and 129 holdings, its largest position is Abbvie Inc (14.7%) and the top 10 make up 46.9% of the portfolio.

What to watch

  • Expensive for its category (1.69%)
  • 12b-1 marketing fee of 1% a year

Updated Nov 19, 2026

What FBTCX invests in

Fidelity Advisor Biotechnology Fund seeks capital appreciation.

Normally investing primarily in common stocks. Normally investing at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. These companies may include, for example, companies engaged in the research, development, manufacturing, or marketing of products based in whole or in part on genetic analysis and genetic engineering. Fidelity may consider a company to be principally engaged in the designated business activity or activities based on: (i) the level of a company's assets, income, sales, or profits that are committed to, derived from, or related to the designated business activity or activities, or (ii) whether a third party has given the company an…

From the fund's prospectus (filed Sep 24, 2026).

FBTCX performance

Average annual total returns
1 yr5 yr10 yr
FBTCX+37.5%+6.8%+7.7%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Sep 30, 2026

Full FBTCX performance history →

What FBTCX costs

On a $10,000 investment, FBTCX's 1.69% expense ratio costs about $169 a year. The prospectus estimates $1,799 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full FBTCX fee table →

FBTCX top 10 holdings

#Holding% of fund
1Abbvie Inc14.71%
2Gilead Sciences Inc5.70%
3Spyre Therapeutics Inc3.83%
4Alnylam Pharmaceuticals Inc3.62%
5Dianthus Therapeutics Inc3.55%
6Cogent Biosciences Inc3.25%
7Oruka Therapeutics Inc3.24%
8Insmed Inc3.05%
9Revolution Medicines Inc3.00%
10Argenx Se3.00%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 46.9% of the fund. See all top 25 holdings and asset mix →

Alternatives to FBTCX

More funds like FBTCX →

FBTCX FAQ

What is the expense ratio of FBTCX?
FBTCX's expense ratio is 1.69%, which works out to about $169 a year for every $10,000 invested. The prospectus estimates total costs of $1,799 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is FBTCX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.69%); 12b-1 marketing fee of 1% a year. This is general information, not personalized advice.
What does FBTCX hold?
FBTCX's largest holdings are Abbvie Inc (14.7%), Gilead Sciences Inc (5.7%), Spyre Therapeutics Inc (3.8%), Alnylam Pharmaceuticals Inc (3.6%), Dianthus Therapeutics Inc (3.5%). It holds 129 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is FBTCX's 5-year return?
FBTCX returned +6.8% a year over the five years ending Sep 30, 2026, and +7.7% a year over ten years. Past performance does not guarantee future results.
Who manages FBTCX?
FBTCX is offered by Fidelity through Fidelity Advisor Series Vii.